NovaBridge Biosciences
0VY
Company Profile
Business description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
32
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,221.20 | 37.00 | 0.40% |
| CAC 40 | 8,313.12 | 17.84 | -0.21% |
| DAX 40 | 25,352.39 | 66.15 | 0.26% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,238.94 | 54.59 | 0.54% |
| HKSE | 26,853.90 | 69.72 | -0.26% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,969.74 | 140.76 | -0.26% |
| NZX 50 Index | 13,717.38 | 57.59 | 0.42% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,897.90 | 36.20 | 0.41% |
| SSE Composite Index | 4,103.45 | 9.16 | -0.22% |